Technical Analysis for KYMR - Kymera Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Up | Up |
| Historical KYMR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| 180 Bullish Setup | Bullish Swing Setup | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 10.26% | |
| Multiple of Ten Bearish | Other | 10.26% | |
| Wide Bands | Range Expansion | 10.26% | |
| MACD Bullish Signal Line Cross | Bullish | 5.12% | |
| Multiple of Ten Bullish | Other | 5.12% | |
| Wide Bands | Range Expansion | 5.12% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Rose Above Previous Day's High | about 12 hours ago | |
| Up 1 ATR | about 12 hours ago | |
| Up 5% | about 13 hours ago | |
| 60 Minute Opening Range Breakout | about 13 hours ago | |
| Up 3% | about 15 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Autoimmune Diseases Rheumatoid Arthritis Autoimmunity Hematologic Malignancies Dermatitis Atopic Dermatitis Hidradenitis Suppurativa
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Autoimmune Diseases Rheumatoid Arthritis Autoimmunity Hematologic Malignancies Dermatitis Atopic Dermatitis Hidradenitis Suppurativa
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 91.92 |
| 52 Week Low | 25.43 |
| Average Volume | 186,645 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 61.06 |
| 20-Day Moving Average | 75.20 |
| 10-Day Moving Average | 75.68 |
| Average True Range | 7.36 |
| ADX | 34.12 |
| +DI | 33.38 |
| -DI | 16.43 |
| Chandelier Exit (Long, 3 ATRs ) | 69.84 |
| Chandelier Exit (Short, 3 ATRs ) | 81.53 |
| Upper Bollinger Band | 90.13 |
| Lower Bollinger Band | 60.28 |
| Percent B (%b) | 0.84 |
| BandWidth | 39.69 |
| MACD Line | 5.48 |
| MACD Signal Line | 5.16 |
| MACD Histogram | 0.3241 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 99.92 | ||||
| Resistance 3 (R3) | 98.79 | 92.83 | 97.51 | ||
| Resistance 2 (R2) | 92.83 | 89.15 | 93.40 | 96.71 | |
| Resistance 1 (R1) | 89.15 | 86.88 | 90.99 | 90.28 | 95.90 |
| Pivot Point | 83.19 | 83.19 | 84.12 | 83.76 | 83.19 |
| Support 1 (S1) | 79.51 | 79.51 | 81.35 | 80.64 | 75.02 |
| Support 2 (S2) | 73.55 | 77.24 | 74.12 | 74.21 | |
| Support 3 (S3) | 69.87 | 73.55 | 73.41 | ||
| Support 4 (S4) | 71.00 |
